122 studies found for:    Open Studies | niaid
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | niaid
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Interferon Responses in Eczema Herpeticum (ADEH)
Conditions: Atopic Dermatitis;   Eczema Herpeticum;   Herpes Simplex Infections;   Eczema Vaccinatum
Intervention:
2 Not yet recruiting Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
Condition: HIV Infections
Intervention: Drug: Ruxolitinib
3 Not yet recruiting Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction
Conditions: Liver Transplant Recipient;   Living Donor (of the Respective Liver Transplant Recipient)
Interventions: Biological: darTregs;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Drug: Immunosuppression (IS) Withdrawal;   Procedure: Study Mandated Procedures
4 Not yet recruiting Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
Condition: HIV Infections
Intervention: Biological: VRC01
5 Not yet recruiting Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
Condition: Dengue
Interventions: Biological: Recombinant live attenuated trivalent dengue vaccine;   Biological: Placebo;   Biological: rDEN2Δ30-7169 vaccine
6 Not yet recruiting Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX®-GP HIV-1 DNA vaccine;   Biological: Interleukin-12 (IL-12) DNA adjuvant;   Biological: Placebo
7 Not yet recruiting Polyclonal Tregs for Lupus
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Discoid;   Lupus Erythematosus, Systemic
Intervention: Biological: Polyclonal Regulatory T Cells
8 Not yet recruiting Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048
Condition: HIV Infections
Interventions: Drug: MK-2048A IVR (Low Dose);   Drug: MK-2048A IVR (Original Dose)
9 Not yet recruiting Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo
10 Recruiting A Safety and Immune Response Study of 2 Experimental HIV Vaccines
Condition: HIV Infection
Interventions: Biological: ALVAC-HIV;   Biological: Bivalent Subtype C gp120/MF59®;   Biological: ALVAC-HIV (vCP2438) Placebo;   Biological: Bivalent gp120/MF59® Placebo
11 Recruiting Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
Condition: Dengue
Interventions: Biological: rDEN1Δ30;   Biological: Placebo;   Biological: rDEN2Δ30-7169
12 Recruiting Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048
Condition: HIV Infections
Interventions: Device: Vicriviroc (MK-4176) Intravaginal Ring (IVR);   Device: MK-2048 IVR;   Device: MK-2048A IVR;   Device: Placebo IVR
13 Recruiting Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Conditions: HIV Infections;   Cardiovascular Diseases
Interventions: Drug: Pitavastatin;   Drug: Placebo
14 Recruiting Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand
Condition: Dengue
Interventions: Biological: TV003;   Biological: Placebo for TV003
15 Recruiting Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis
Condition: Secondary Progressive Multiple Sclerosis
Interventions: Procedure: Blood Draw;   Procedure: CSF collection by lumbar puncture (Optional)
16 Recruiting A Clinical Trial of Fel d 1 Peptide Immunotherapy
Conditions: Cat Allergy;   Cat Hypersensitivity
Interventions: Drug: Cat-PAD;   Drug: Placebo for Cat-PAD
17 Recruiting Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA Nat-B env;   Biological: DNA CON-S env;   Biological: DNA Mosaic env;   Biological: MVA-CMDR;   Biological: Placebo for DNA Nat-B env;   Biological: Placebo for DNA CON-S env;   Biological: Placebo for DNA Mosaic env;   Biological: Placebo for MVA-CMDR
18 Recruiting Tocilizumab (TCZ) in New-onset Type 1 Diabetes
Conditions: Type 1 Diabetes Mellitus;   New-onset Type 1 Diabetes Mellitus;   T1DM;   T1D
Interventions: Drug: Tocilizumab (TCZ);   Drug: Placebo
19 Recruiting Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
Conditions: Influenza A;   Influenza B
Interventions: Biological: Intravenous hyperimmune immunoglobulin (IVIG);   Biological: Placebo for IVIG
20 Recruiting Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old
Condition: Influenza A Virus, H7N9 Subtype
Interventions: Biological: H7N9 Anhui 2013/AA ca;   Biological: Inactivated subvirion H7N9 vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years